Home › Medical
US
1 of 1 storefronts
Content in en-US
Content in en-US
Information
Apple ID1205990848
Bundle IDcom.garmenmed.MensaGuide
SellerSeller
Min iOS15.6
Device familiesmac, iphone, ipad, ipod
Released2019-03-02
Copyright© GARMENMED SCP 2025
Privacy policyLink ↗
Preview 3 platforms
iPhone 9 images
iPad 9 images
Mac 8 images
What’s New Version 26.27
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudomonas aeruginosa, Rickettsia prowazekii, Tropheryma whipplei; Candida, Lacazia loboi; enterovirus, HBV, influenza, Orthonairovirus, RSV, SARS-CoV-2, VZV. Bacterial prostatitis. Cystitis. Neutropenic fever. Osteomyelitis. Prosthetic joint infection. Sepsis and septic shock. Infections in SOT recipients (prevention).
Description
Mensa Guide is a comprehensive antimicrobial reference designed to support optimal therapeutic decision-making in infectious diseases. Content is structured for rapid access to key information, while allowing seamless exploration of additional details through inline notes.
• Tap on any word in the text to navigate to another entry, check abbreviations, view explanatory notes, open clinical calculators, or access bibliographic references.
• Search directly from almost all screens using clinically relevant criteria, or use full-text search for more specific queries.
• Filter and explore more than 800 pathogens according to microbiological and clinical characteristics.
• Use built-in calculators to estimate serum antibiotic concentrations, glomerular filtration rate, and many more additional clinical parameters and validated scores.
• Rely on continuously updated content, regularly reviewed to reflect evolving resistance patterns, emerging pathogens and antimicrobials, epidemiological trends, and new evidence or treatment guidelines published in leading medical journals.
Note: use of the Mensa Guide requires an annual subscription of $19.99 or a monthly subscription of $1.99 (price may vary by region), with a 30-day free trial period. A subscription allows the use of the Mensa Guide on macOS, iPhone and iPad platforms.
--
About auto-renewing subscriptions:
– An in-app subscription is one month for $1.99 or one year for $19.99.
– Payment will be charged to your iTunes Account at confirmation of purchase.
– Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period.
– Your account will be charged for renewal within 24-hours prior to the end of the current period for $1.99 or $19.99.
– Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user's Account Settings after purchase.
– Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
Terms & Conditions: http://www.garmenmed.com/terms.html
--
Disclaimer:
This app is not intended for the general public but for health care professionals. Although we make every effort to ensure that the data is accurate, we are not responsible for any errors or omissions that the app may contain. The application of the information provided in a particular situation remains the sole responsibility of the health care professional.
--
We would love to hear your suggestions, recommendations or corrections. Contact us at mensaguide@garmenmed.com
In-App Purchases US pricing
Monthly Subscription Subscription
Monthly 1-month free trial$1.99
Annual Subscription Subscription
Yearly 1-month free trial$19.99
Capabilities
In-App Purchases
Accessibility
ipadiphonemacrealityDevicetvoswatch
Version history 25 versions
Build 887788730v26.272026-07-04 22:09:15
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudomonas aeruginosa, Rickettsia prowazekii, Tropheryma whipplei; Candida, Lacazia loboi; enterovirus, HBV, influenza, Orthonairovirus, RSV, SARS-CoV-2, VZV. Bacterial prostatitis. Cystitis. Neutropenic fever. Osteomyelitis. Prosthetic joint infection. Sepsis and septic shock. Infections in SOT recipients (prevention).
Build 887479643v26.262026-06-27 07:16:49
Changes in benzylpenicillin, cefazolin, eravacycline, gepotidacin, imipenem/relebactam, liposomal amphotericin B, posaconazole, remdesivir, ribavirin, tafenoquine, temocillin. Acinetobacter, Clostridioides difficile, Enterobacter, Fusobacterium, Klebsiella, Mycobacterium tuberculosis, Staphylococcus aureus, Stenotrophomonas; Pneumocystis jirovecii, Trichophyton; HPIV, MARV; Blastocystis. Abscesses (intra-abdominal, anorectal, and prostatic). β-lactam-resistant Enterobacterales infections. Pneumonia. Pyelonephritis. Infections associated with immunosuppressive therapies (prophylaxis). Prophylaxis of invasive fungal disease in onco-hematologic patients.
Build 887209621v26.25.12026-06-20 15:37:10
Minor bug fixes, including a correction to the MAGIC criteria evaluation.
Build 887186293v26.252026-06-19 22:58:41
• Added MAGIC criteria for VGEI to Utilities.
• Changes in amoxicillin, bedaquiline, colistin, dalbavancin, fluconazole, levofloxacin, olorofim, voriconazole, zanamivir. Acinetobacter, Burkholderia pseudomallei, Clostridium spp, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas, Streptococcus gallolyticus, Treponema pallidum; Lomentospora, Mucor, Scedosporium; HHV-6, influenza, OROV. β-lactam-resistant Enterobacterales infections. Biomarkers of inflammation/infection. Sepsis and septic shock. Infections in neutropenic patients (prevention). Influenza vaccination. Surgical site infection prevention. Venous catheter infection prevention.
Build 886820671v26.242026-06-13 20:54:34
• Added bepirovirsen and cefepime/zidebactam to Antimicrobials.
• Changes in fosmanogepix, ibrexafungerp, maribavir, olorofim, and ECOFF values (aztreonam/avibactam). Sphingomonas, Stenotrophomonas; Aspergillus, Candida; CMV, Ebola, EBV, HBV, MPXV; Plasmodium falciparum. Infections in patients with liver cirrhosis. Pneumonia. Prosthetic joint infection. Asymptomatic bacteriuria (UTI prevention). RSV vaccination. Venous catheter infection (prevention).
Build 886571732v26.232026-06-06 20:03:05
• Added a PaO₂ estimation calculator (from SpO₂).
• Changes in cefiderocol, ceftriaxone, dalbavancin, eravacycline, isoniazid, tigecycline. Enterococcus, Mycobacterium tuberculosis, Pneumocystis jirovecii; CMV, SARS-CoV-2; Babesia. Prosthetic joint infection. Viral hemorrhagic fevers. CMV prophylaxis. HPV vaccination. RSV vaccination. Shingles (herpes zoster) vaccination. Surgical site infection prophylaxis. Toxoplasma gondii (prevention in hematologic patients).
Build 886282711v26.222026-05-30 21:06:46
• Added a new entry on infections in patients with major burns (under Syndromes).
• Changes in bictegravir, cabotegravir, cefiderocol, ensitrelvir, ertapenem, nitrofurantoin, pristinamycin, zoliflodacin. Chlamydia psittaci, Mycobacterium xenopi, Mycoplasma genitalium, Neisseria gonorrhoeae, Pseudomonas aeruginosa; Diutina, Purpureocillium; CMV, JCPyV, KFDV, RSV, SARS-CoV-2; Echinococcus granulosus, Leishmania. Biomarkers of inflammation/infection. Infections during CAR T-cell therapy. Pneumonia. CMV prophylaxis. RSV prevention. RSV vaccination. Tuberculosis prevention.
Build 885987947v26.212026-05-25 18:21:11
• Added Dermatophilus congolensis (under Pathogens).
• Changes in azithromycin, aztreonam/avibactam, cefepime/taniborbactam, cefiderocol, colistin, isoniazid. Enterobacter, Mycobacterium chelonae, Pseudomonas aeruginosa, Shigella, Streptococcus pneumoniae; CMV, EBOV, Mpox, SARS-CoV-2. Encephalitis. Exacerbations of COPD. Facial palsy. Peritonitis. Treatment of β-lactam-resistant Enterobacterales infections.
Build 885723667v26.202026-05-16 08:10:46
Changes in amphotericin B deoxycholate, bictegravir, daptomycin, tecovirimat. Butyricimonas, CoNS, Escherichia coli, Gardnerella, Haemophilus influenzae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Shewanella, Staphylococcus aureus, Streptococcus agalactiae; Arthrographis kalrae, Candida, Trichophyton; LASV, MPXV, SARS-CoV-2, WNV; Sarcoptes scabiei, Schistosoma. Acute meningitis. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Infections of the eyelid. Sepsis and septic shock. Infections in solid organ transplant recipients (prevention). Influenza vaccination. RSV prevention.
Build 885435963v26.192026-05-10 05:25:46
Changes in anidulafungin, bedaquiline, ganciclovir, imipenem/relebactam, micafungin, omadacycline, pretomanid, voriconazole. Clostridioides dificile, CoNS, Gordonia, Mycobacterium kansasii, Mycobacterium tuberculosis, Paenibacillus, Staphylococcus aureus; Aspergillus, Cryptococcus neoformans and C. gattii; HIV, Orthohantavirus, RSV, YFV. Brain abscess. Infections of the spine. Respiratory infections in cystic fibrosis. Sepsis and septic shock. Sinusitis. Recurrent urinary tract infection. Surgical site infection (prophylaxis).
Build 885130106v26.182026-05-03 20:10:06
Changes in cefiderocol, colistin, gepotidacin, imipenem/relebactam, lenacapavir, olorofim. Bacteroides, Citrobacter, Enterococcus, Providencia, Staphylococcus aureus, Streptococcus agalactiae; Candida; dengue, NiV, rhinovirus, RSV, SARS-CoV-2. Guillain-Barré syndrome. Pleural effusion of infectious origin. Sepsis and septic shock. Malaria (prevention). Surgical site infection (prevention).
Build 884904935v26.172026-04-26 21:00:43
• Added the DENOVi score (E. faecalis bacteremia).
• Changes in amoxicillin, amoxicillin/clavulanate, cabotegravir, imipenem/relebactam, isavuconazole, linezolid, meropenem/vaborbactam, posaconazole, sulbactam/durlobactam, voriconazole. Clostridioides difficile, Enterococcus, Escherichia coli, Leptospira, Staphylococcus aureus, Streptobacillus moniliformis; Aspergillus, Sporothrix; influenza; Plasmodium falciparum. Cervicitis. Exacerbations of COPD. Prosthetic joint infection. Treatment of β-lactam-resistant Enterobacterales infections. COVID-19 vaccination. Influenza (chemoprophylaxis). Infections in solid organ transplant recipients (prevention).
Build 884602427v26.162026-04-20 06:49:26
Changes in amoxicillin/clavulanate, amphotericin B (liposomal and deoxycholate), cabotegravir, ceftazidime/avibactam, posaconazole, quinolones, rilpivirine. Klebsiella, Pseudomonas aeruginosa; Aspergillus, Candida, Cryptococcus neoformans; Trypanosoma cruzi. Bacterial prostatitis. Cystitis. Infective endocarditis. Osteomyelitis. Prosthetic joint infection. Skin, subcutaneous tissue, and fascia infections. Toxic shock syndrome. Chikungunya vaccination. Dengue vaccination. Human papillomavirus vaccination. Infections in neutropenic patients (prevention). Pertussis prevention. Pertussis vaccination. RSV vaccination.
Build 884391582v26.152026-04-12 22:01:36
Changes in aztreonam/avibactam, bedaquiline, clofazimine, contezolid, dihydroartemisinin/piperaquine, glycopeptides, linezolid, meropenem/vaborbactam, molnupiravir, nirmatrelvir/ritonavir, penicillins, rifabutin. Acinetobacter, Klebsiella, Pseudomonas aeruginosa; Candida; influenza, MPXV, norovirus. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Pneumonia. Sepsis and septic shock. Influenza vaccination. Recurrent urinary tract infection. Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Venous catheter infection (prevention).
Build 884112464v26.142026-04-05 23:03:14
Changes in cefepime, dalbavancin, daptomycin, doxycycline, eravacycline, isavuconazole, linezolid, quinolones. Acinetobacter, Anaplasma, Bacillus spp, Bartonella, Borrelia burgdorferi, Corynebacterium, Mycoplasma spp, Stenotrophomonas, Treponema pallidum; Aspergillus, Candida, Coccidioides, Pneumocystis jirovecii, Rasamsonia; EBV, HBV, YFV. Brain abscess. Infectious endocarditis. Pancreatic infections. Lyme disease prevention.
Build 883882717v26.132026-03-29 21:44:36
Changes in ciprofloxacin, daptomycin, gepotidacin, oritavancin, quinolones, zoliflodacin. Helicobacter, Mycobacterium tuberculosis; Aspergillus, Schizophyllum; influenza. Infective endocarditis. Pleural effusion of infectious origin. Prosthetic joint infection. Sepsis and septic shock. Sinusitis. Toxic shock syndrome. Urethritis. Chikungunya vaccination. Infections associated with immunosuppressive therapies (prophylaxis). Infective endocarditis (prophylaxis). Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Surgical site infection prevention.
Build 883601801v26.122026-03-23 00:06:32
Changes in dalbavancin. BCG, Clostridioides difficile, Enterococcus, Fusobacterium, Mycobacterium tuberculosis, Neisseria meningitidis, Roseomonas, Staphylococcus aureus; Candida; Trypanosoma cruzi. Biomarkers of inflammation/infection. Neutropenic enterocolitis. Pneumonia. Sepsis and septic shock. Vaginitis. Meningococcal meningitis (prevention). Recurrent vulvovaginal candidiasis. Surgical site infection (prophylaxis). Tuberculosis prevention.
Build 883361094v26.112026-03-14 20:22:22
• Inclusion of the tetanus severity score (TSS).
• Changes in carbapenems, cefepime, cefepime/enmetazobactam, faropenem, fostemsavir, gepotidacin, omadacycline, penicillins. Acinetobacter, Mycobacterium tuberculosis, Mycobacteroides chelonae, Pseudomonas aeruginosa, Streptococcus pneumoniae; Aspergillus, Candida, Cryptococcus neoformans, Mucor, Pneumocystis jirovecii, Trichophyton; HSV-1, SARS-CoV-2. Encephalitis. Infectious arthritis. Intravenous catheter infection. Neutropenic fever and in HSCT recipients. Pneumonia. Sepsis and septic shock. COVID-19 vaccination. Prophylaxis of invasive fungal disease. RSV vaccination. VEXAS syndrome (infection prevention).
Build 883117404v26.102026-03-09 12:19:51
• Inclusion of the SOFA-2 score (updated SOFA) and the AURIS score (C. auris candidemia).
• Changes in daptomycin, fluconazole, gentamicin, ibrexafungerp, isavuconazole, oteseconazole, posaconazole, sertaconazole, teicoplanin, voriconazole. Bacillus anthracis, Clostridioides difficile, Legionella, Mycobacteroides chelonae, Mycoplasma pneumoniae, Pluralibacter, Staphylococcus aureus, Treponema pallidum; Candida, Coccidioides, Gloniopsis, Talaromyces; Oestrus ovis. Pneumonia. Sepsis and septic shock. Vaginitis. Recurrent vulvovaginal candidiasis.
Build 882882498v26.92026-03-02 11:55:21
• Inclusion of a linezolid TDM predictive score for identifying out-of-range exposure risks.
• Changes in aztreonam/avibactam, dapsone, daptomycin, gepotidacin, itraconazole, meropenem, posaconazole, tecovirimat. Borrelia burgdorferi, Klebsiella, Lactobacillus, Leptospira, Mycobacterium leprae, Neisseria meningitidis, Staphylococcus aureus, Streptococcus agalactiae; Candida; HCV, HDV, MPXV. Exacerbations of COPD. Fever and rash. Odontogenic infections. Pharyngotonsillitis. Pneumonia. Sepsis and septic shock. Group B streptococcus (prevention of maternal and neonatal infection). Infections associated with immunosuppressive therapies (prophylaxis). RSV vaccination.
Build 882652014v26.82026-02-23 12:19:01
Changes in acyclovir, amikacin, ceftazidime/avibactam, zoliflodacin. Clostridium tetani, Cryptococcus neoformans, Franklinella schreckenbergeri, Legionella, Leptospira, Neisseria meningitidis, Spodiobacter cordis, Vandammella animalimorsus; Apophysomyces, Cunninghamella, Mucor, Pythium, Saksenaea; EBV, HIV, MPXV, RSV; Plasmodium spp. Allergy to antibiotics. Fever in neutropenic patients. Infections of the spine or spinal implants. Pyelonephritis. Sepsis and septic shock. Treatment of β-lactam-resistant Enterobacterales infections. HIV infection prophylaxis. Premature rupture of membranes (infection prevention). Surgical site infection prophylaxis. Tetanus vaccination.
Build 882447845v26.72026-02-16 11:59:12
• Inclusion of CAR-HEMATOTOX score.
• Changes in colistin, eravacycline, fosmanogepix, ECOFF values (erythromycin). Actinobacillus, Aggregatibacter, Capnocytophaga, Cardiobacterium, Chlamydia trachomatis, Chromobacterium, Dysgonomonas, Kingella, Klebsiella, Pasteurella, Pseudostreptobacillus hongkongensis, Streptobacillus moniliformis, Streptococcus suis, Suttonella indologenes; influenza; Leishmania spp. Bacterial prostatitis. Infectious arthritis. Pneumonia. Prosthetic joint infection. Pyelonephritis. Sepsis and septic shock. Exacerbations of COPD. Shingles vaccination. Surgical site infection prevention. Tuberculosis prevention.
Build 882243443v26.62026-02-09 11:38:57
Changes in cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, colistin, moxifloxacin, rifampicin, temocillin. Campylobacter, Clostridioides difficile, Cutibacterium, Mycobacterium tuberculosis, Pseudomonas aeruginosa, rapidly growing mycobacteria, Staphylococcus aureus; Candida, Cryptococcus neoformans; EBV, influenza, Rocahepevirus ratti, TTV. Brain abscess. Fever in travelers returning from the tropics. Infectious adenitis. Infectious diarrhea. Pericarditis. Pneumonia. Vaginitis. HAV vaccination. Pneumonia associated with mechanical ventilation (prevention).
Build 882026332v26.52026-02-02 11:32:38
Changes in amphotericin B deoxycholate, cefepime, ceftaroline, eravacycline, lefamulin, rezafungin. Bordetella, Citrobacter, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Streptococcus suis; Mucor; HSV, norovirus, SARS-CoV-2. Appendicitis. Biomarkers of inflammation/infection. Encephalitis. Treatment of β-lactam-resistant Enterobacterales infections. Tuberculosis prevention.
Build 881797410v26.42026-01-26 14:10:29
Changes in ceftolozane/tazobactam, monoclonal antibodies. CoNS, Mycobacterium tuberculosis, Proteus; Candida, Pichia, Yarrowia lipolytica; dengue, HBoV, HCV, VZV; Babesia, Sarcoptes scabiei, Strongyloides. Cardiac implantable electronic device infections. Exacerbations of COPD. Diabetic foot ulcer infections. Intravenous catheter infection. Myocarditis. Pericarditis. Pneumonia. Pyelonephritis. Sepsis and septic shock. Dengue vaccination. Infection in vaginal delivery (prevention). RSV vaccination.
Price history by region
Currency
Show
Columns
Search
Availability 1 of 1 storefronts
| Region | Language | Price | Ratings | Avg | Version |
|---|---|---|---|---|---|
| US | en-US | Free | 0 | — | 26.27 |
Change log 29 changes · US
✎
releaseNotes updated
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudo
✎
description updated
Mensa Guide is a comprehensive antimicrobial reference designed to support optimal therapeutic decision-making in infectious diseases. Content is structured for
✎
subtitle updated
Updated Antimicrobial Therapy
✎
name updated
Mensa Guide
◆
Version 26.27 released
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudomonas aeruginosa, Rickettsia prowazekii, Tropheryma whipplei; Candida, Lacazia l
◆
Version 26.26 released
Changes in benzylpenicillin, cefazolin, eravacycline, gepotidacin, imipenem/relebactam, liposomal amphotericin B, posaconazole, remdesivir, ribavirin, tafenoquine, temocillin. Acinetobacter, Clostridioides difficile, Enterobacter, Fusobacte
◆
Version 26.25.1 released
Minor bug fixes, including a correction to the MAGIC criteria evaluation.
◆
Version 26.25 released
• Added MAGIC criteria for VGEI to Utilities.
• Changes in amoxicillin, bedaquiline, colistin, dalbavancin, fluconazole, levofloxacin, olorofim, voriconazole, zanamivir. Acinetobacter, Burkholderia pseudomallei, Clostridium spp, Mycobacteri
◆
Version 26.24 released
• Added bepirovirsen and cefepime/zidebactam to Antimicrobials.
• Changes in fosmanogepix, ibrexafungerp, maribavir, olorofim, and ECOFF values (aztreonam/avibactam). Sphingomonas, Stenotrophomonas; Aspergillus, Candida; CMV, Ebola, EBV, HB
◆
Version 26.23 released
• Added a PaO₂ estimation calculator (from SpO₂).
• Changes in cefiderocol, ceftriaxone, dalbavancin, eravacycline, isoniazid, tigecycline. Enterococcus, Mycobacterium tuberculosis, Pneumocystis jirovecii; CMV, SARS-CoV-2; Babesia. Prosthet
◆
Version 26.22 released
• Added a new entry on infections in patients with major burns (under Syndromes).
• Changes in bictegravir, cabotegravir, cefiderocol, ensitrelvir, ertapenem, nitrofurantoin, pristinamycin, zoliflodacin. Chlamydia psittaci, Mycobacterium xe
◆
Version 26.21 released
• Added Dermatophilus congolensis (under Pathogens).
• Changes in azithromycin, aztreonam/avibactam, cefepime/taniborbactam, cefiderocol, colistin, isoniazid. Enterobacter, Mycobacterium chelonae, Pseudomonas aeruginosa, Shigella, Streptoco
◆
Version 26.20 released
Changes in amphotericin B deoxycholate, bictegravir, daptomycin, tecovirimat. Butyricimonas, CoNS, Escherichia coli, Gardnerella, Haemophilus influenzae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Shewanella, Staphylococcus aureus,
◆
Version 26.19 released
Changes in anidulafungin, bedaquiline, ganciclovir, imipenem/relebactam, micafungin, omadacycline, pretomanid, voriconazole. Clostridioides dificile, CoNS, Gordonia, Mycobacterium kansasii, Mycobacterium tuberculosis, Paenibacillus, Staphyl
◆
Version 26.18 released
Changes in cefiderocol, colistin, gepotidacin, imipenem/relebactam, lenacapavir, olorofim. Bacteroides, Citrobacter, Enterococcus, Providencia, Staphylococcus aureus, Streptococcus agalactiae; Candida; dengue, NiV, rhinovirus, RSV, SARS-CoV
◆
Version 26.17 released
• Added the DENOVi score (E. faecalis bacteremia).
• Changes in amoxicillin, amoxicillin/clavulanate, cabotegravir, imipenem/relebactam, isavuconazole, linezolid, meropenem/vaborbactam, posaconazole, sulbactam/durlobactam, voriconazole. Clo
◆
Version 26.16 released
Changes in amoxicillin/clavulanate, amphotericin B (liposomal and deoxycholate), cabotegravir, ceftazidime/avibactam, posaconazole, quinolones, rilpivirine. Klebsiella, Pseudomonas aeruginosa; Aspergillus, Candida, Cryptococcus neoformans;
◆
Version 26.15 released
Changes in aztreonam/avibactam, bedaquiline, clofazimine, contezolid, dihydroartemisinin/piperaquine, glycopeptides, linezolid, meropenem/vaborbactam, molnupiravir, nirmatrelvir/ritonavir, penicillins, rifabutin. Acinetobacter, Klebsiella,
◆
Version 26.14 released
Changes in cefepime, dalbavancin, daptomycin, doxycycline, eravacycline, isavuconazole, linezolid, quinolones. Acinetobacter, Anaplasma, Bacillus spp, Bartonella, Borrelia burgdorferi, Corynebacterium, Mycoplasma spp, Stenotrophomonas, Trep
◆
Version 26.13 released
Changes in ciprofloxacin, daptomycin, gepotidacin, oritavancin, quinolones, zoliflodacin. Helicobacter, Mycobacterium tuberculosis; Aspergillus, Schizophyllum; influenza. Infective endocarditis. Pleural effusion of infectious origin. Prosth
◆
Version 26.12 released
Changes in dalbavancin. BCG, Clostridioides difficile, Enterococcus, Fusobacterium, Mycobacterium tuberculosis, Neisseria meningitidis, Roseomonas, Staphylococcus aureus; Candida; Trypanosoma cruzi. Biomarkers of inflammation/infection. Neu
◆
Version 26.11 released
• Inclusion of the tetanus severity score (TSS).
• Changes in carbapenems, cefepime, cefepime/enmetazobactam, faropenem, fostemsavir, gepotidacin, omadacycline, penicillins. Acinetobacter, Mycobacterium tuberculosis, Mycobacteroides chelona
◆
Version 26.10 released
• Inclusion of the SOFA-2 score (updated SOFA) and the AURIS score (C. auris candidemia).
• Changes in daptomycin, fluconazole, gentamicin, ibrexafungerp, isavuconazole, oteseconazole, posaconazole, sertaconazole, teicoplanin, voriconazole.
◆
Version 26.9 released
• Inclusion of a linezolid TDM predictive score for identifying out-of-range exposure risks.
• Changes in aztreonam/avibactam, dapsone, daptomycin, gepotidacin, itraconazole, meropenem, posaconazole, tecovirimat. Borrelia burgdorferi, Klebs
◆
Version 26.8 released
Changes in acyclovir, amikacin, ceftazidime/avibactam, zoliflodacin. Clostridium tetani, Cryptococcus neoformans, Franklinella schreckenbergeri, Legionella, Leptospira, Neisseria meningitidis, Spodiobacter cordis, Vandammella animalimorsus;
◆
Version 26.7 released
• Inclusion of CAR-HEMATOTOX score.
• Changes in colistin, eravacycline, fosmanogepix, ECOFF values (erythromycin). Actinobacillus, Aggregatibacter, Capnocytophaga, Cardiobacterium, Chlamydia trachomatis, Chromobacterium, Dysgonomonas, King
◆
Version 26.6 released
Changes in cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, colistin, moxifloxacin, rifampicin, temocillin. Campylobacter, Clostridioides difficile, Cutibacterium, Mycobacterium tuberculosis, Pseudomonas aeruginosa, rapidly growi
◆
Version 26.5 released
Changes in amphotericin B deoxycholate, cefepime, ceftaroline, eravacycline, lefamulin, rezafungin. Bordetella, Citrobacter, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Streptococcus suis; Mucor; HSV, norovirus, SARS-CoV-2. Appendicitis.
◆
Version 26.4 released
Changes in ceftolozane/tazobactam, monoclonal antibodies. CoNS, Mycobacterium tuberculosis, Proteus; Candida, Pichia, Yarrowia lipolytica; dengue, HBoV, HCV, VZV; Babesia, Sarcoptes scabiei, Strongyloides. Cardiac implantable electronic dev